Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Aptose licenses molecule program to OHM Oncology
April 2018
SHARING OPTIONS:

SAN DIEGO—Aptose Biosciences Inc. recently signed an exclusive global license providing OHM Oncology with the rights to develop, manufacture and commercialize APL-581 and related molecules from Aptose’s dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. Aptose retains reacquisition rights to certain molecules, and OHM will have the rights to develop and sublicense all other molecules. Per the agreement, OHM will pay Aptose a nominal upfront cash payment, as well as up to $125 million in additional payments if certain development, regulatory and sales milestones are reached. Aptose is also eligible to receive significant royalties on future sales.
 
“We are pleased to formalize a new phase of our partnership with OHM Oncology, which originated in late 2015 from the work performed by its R&D partner LAXAI Life Sciences on a discovery stage program,” said Dr. William G. Rice, Aptose’s chairman, president and CEO.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.